scholarly journals Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence

2019 ◽  
Vol 3 (1) ◽  
pp. 8-15.e1 ◽  
Author(s):  
Usha Chakravarthy ◽  
Vladimir Bezlyak ◽  
Alexandros Sagkriotis ◽  
Ray Griner ◽  
Adrian Skelly ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Real World ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Real World Evidence

scholarly journals SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States

2020 ◽  
Vol 4 (2) ◽  
pp. 122-133 ◽  
Author(s):  
Arshad M. Khanani ◽  
Adrian Skelly ◽  
Vladimir Bezlyak ◽  
Ray Griner ◽  
Laura Rodriguez Torres ◽  
...  
Keyword(s):  
United States ◽  
Macular Degeneration ◽  
Real World ◽  
The United States ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Real World Evidence

scholarly journals Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence

2020 ◽  
pp. bjophthalmol-2020-317434
Author(s):  
Vincent Daien ◽  
Robert P Finger ◽  
James S Talks ◽  
Paul Mitchell ◽  
Tien Y Wong ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Real World ◽  
Treatment Strategies ◽  
Age Related Macular Degeneration ◽  
Fixed Dose ◽  
Treatment Burden ◽  
Visual Outcomes ◽  
Anti Vegf ◽  
Age Related ◽  
Real World Evidence

The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD).A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD.The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens.RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.

scholarly journals Achieving balance in the treatment and monitoring of neovascular age‐related macular degeneration in the real world: lessons from the Netherlands cohort of the AURA study

2018 ◽  
Vol 97 (2) ◽  
Author(s):  
Freekje Asten ◽  
Yvonne Jong‐Hesse ◽  
Janneke J. C. Lith‐Verhoeven ◽  
Frank D. Verbraak ◽  
Johannes G. F. Vromans ◽  
...  
Keyword(s):  
The Netherlands ◽  
Macular Degeneration ◽  
Real World ◽  
Age Related Macular Degeneration ◽  
The Real ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document